Observational study on patterns of neuromuscular blockade reversal

BMC Anesthesiology

Table 3 Neuromuscular Blocking Agent dose by last documented Train-of-Four prior to reversal and Body Mass Index category

	Total dose of NMB (ED 95 equivalent)^a	Last dose of NMB (ED 95 equivalent)^a	Time between last NMB & first neostigmine dose (minutes)^b	Time between first neostigmine dose & extubation (minutes)^b
	Median [IQR]	Median [IQR]	Median [IQR]	Median [IQR]
Last TOF prior to reversal
0/4	3.5 [2.4, 5.2]	1.3 [0.7, 2.4]	52.0 [36.0, 80.3]	12.0 [8.0, 18.0]
1/4	4.0 [2.8, 5.8]	0.8 [0.5, 1.7]	42.0 [29.0, 59.0]	12.5 [8.0, 19.0]
2/4	4.0 [2.8, 5.9]	0.7 [0.4, 1.4]	43.6 [31.0, 61.0]	12.8 [8.0, 18.9]
3/4	4.0 [2.7, 5.8]	0.7 [0.4, 1.5]	49.0 [35.0, 68.0]	12.4 [8.0, 19.0]
4/4	3.5 [2.5, 5.3]	0.8 [0.5, 1.8]	65.0 [44.0, 95.0]	12.7 [8.0, 19.0]
Undocumented	3.3 [2.2, 5.1]	0.7 [0.4, 1.8]	43.0 [24.0, 76.0]	12.0 [7.3, 18.0]
WHO BMI category^c
Underweight	2.9 [2.0, 4.4]	0.8 [0.5, 1.6]	57.4 [39.0, 86.4]	13.8 [9.0, 21.0]
Normal Weight	3.3 [2.2, 4.9]	0.8 [0.4, 1.8]	58.0 [39.0, 86.0]	13.0 [8.0, 19.0]
Overweight	3.6 [2.5, 6.3]	0.7 [0.4, 1.8]	58.9 [39.0, 87.9]	12.1 [8.0, 19.0]
Class I Obese	3.8 [2.7, 5.7]	0.8 [0.5, 1.9]	59.0 [39.0, 87.5]	12.1 [8.0, 19.0]
Class II Obese	4.0 [2.7, 5.9]	0.8 [0.5, 2.0]	58.5 [39.1, 88.1]	12.3 [8.0, 19.0]
Class III Obese	4.2 [2.9, 6.3]	0.8 [0.5, 1.9]	57.0 [38.0, 85.0]	12.9 [8.0, 19.0]

ED95 effect dose for which 95 % of the population exhibits the effect, TOF train-of-four, WHO World Health Organization, BMI body mass index
^aOnly among patients with IBW between 40 and 250 kg
^bOnly among patients receiving neostigmine
^cOnly among patients with BMI between 10 and 80

ISSN: 1471-2253